Regulated Tristetraprolin Overexpression Dampens the Development and Pathogenesis of Experimental Autoimmune Uveitis.
IFNγ
IL-17
autoimmunity
experimental autoimmune uveitis (EAU)
immunoregulation, tristetraprolin (TTP)
inflammatory cytokine
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
07
2020
accepted:
07
12
2020
entrez:
11
2
2021
pubmed:
12
2
2021
medline:
16
6
2021
Statut:
epublish
Résumé
Non-infectious uveitis, a common cause of blindness in man, is often mediated by autoimmunity, a process in which cytokines play major roles. The biosynthesis and secretion of pro-inflammatory cytokines are regulated in part by tristetraprolin (TTP), an endogenous anti-inflammatory protein that acts by binding directly to specific sequence motifs in the 3'-untranslated regions of target mRNAs, promoting their turnover, and inhibiting synthesis of their encoded proteins. We recently developed a TTP-overexpressing mouse (TTPΔARE) by deleting an AU-rich element (ARE) instability motif from the TTP mRNA, resulting in increased accumulation of TTP mRNA and protein throughout the animal. Here, we show that homozygous TTPΔARE mice are resistant to the induction of experimental autoimmune uveitis (EAU) induced by interphotoreceptor retinoid-binding protein (IRBP), an established model for human autoimmune (noninfectious) uveitis. Lymphocytes from TTPΔARE mice produced lower levels of the pro-inflammatory cytokines IFN-γ, IL-17, IL-6, and TNFα than wild type (WT) mice. TTPΔARE mice also produced lower titers of antibodies against the uveitogenic protein. In contrast, TTPΔARE mice produced higher levels of the anti-inflammatory cytokine IL-10, and had higher frequencies of regulatory T-cells, which, moreover, displayed a moderately higher per-cell regulatory ability. Heterozygous mice developed EAU and associated immunological responses at levels intermediate between homozygous TTPΔARE mice and WT controls. TTPΔARE mice were able, however, to develop EAU following adoptive transfer of activated WT T-cells specific to IRBP peptide 651-670, and naïve T-cells from TTPΔARE mice could be activated by antibodies to CD3/CD28. Importantly, TTPΔARE antigen presenting cells were significantly less efficient compared to WT in priming naïve T cells, suggesting that this feature plays a major role in the dampened immune responses of the TTPΔARE mice. Our observations demonstrate that elevated systemic levels of TTP can inhibit the pathogenic processes involved in EAU, and suggest the possible use of TTP-based treatments in humans with uveitis and other autoimmune conditions.
Identifiants
pubmed: 33569048
doi: 10.3389/fimmu.2020.583510
pmc: PMC7868398
doi:
Substances chimiques
Tristetraprolin
0
Zfp36 protein, mouse
0
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
583510Informations de copyright
Copyright © 2021 Xu, Tang, Lyu, Wandu, Stumpo, Mattapallil, Horai, Gery, Blackshear and Caspi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Immunol. 1997 Jul 15;159(2):1004-11
pubmed: 9218623
J Clin Invest. 2010 Sep;120(9):3073-83
pubmed: 20811163
J Control Release. 2018 Sep 10;285:244-251
pubmed: 30009894
PLoS One. 2015 Jun 11;10(6):e0128906
pubmed: 26067490
Mol Cell Biol. 2006 Dec;26(24):9196-208
pubmed: 17030620
Curr Protoc Immunol. 2004 May;Chapter 3:Unit 3.12
pubmed: 18432927
Science. 1998 Aug 14;281(5379):1001-5
pubmed: 9703499
Lancet. 2018 Mar 24;391(10126):1186-1196
pubmed: 29551338
Trends Pharmacol Sci. 2016 Oct;37(10):811-821
pubmed: 27503556
Cell. 2008 May 30;133(5):775-87
pubmed: 18510923
Biochim Biophys Acta. 2013 Jun-Jul;1829(6-7):666-79
pubmed: 23428348
J Leukoc Biol. 2005 Jan;77(1):3-15
pubmed: 15522916
Blood. 2001 Oct 15;98(8):2389-95
pubmed: 11588035
Prog Retin Eye Res. 2004 Nov;23(6):617-37
pubmed: 15388077
Arthritis Rheumatol. 2018 Mar;70(3):427-438
pubmed: 29161463
Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):E6291-E6300
pubmed: 29915044
J Leukoc Biol. 2015 Apr;97(4):723-36
pubmed: 25657290
Methods Mol Biol. 2012;900:443-69
pubmed: 22933083
Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1865-70
pubmed: 26831084
Hum Gene Ther. 2015 Jan;26(1):59-68
pubmed: 25420215
Immunity. 1996 May;4(5):445-54
pubmed: 8630730
J Autoimmun. 1996 Oct;9(5):575-85
pubmed: 8933273
Mol Ther. 2015 May;23(5):875-884
pubmed: 25698151
J Immunol Methods. 2003 Apr 1;275(1-2):251-5
pubmed: 12667688
Invest Ophthalmol Vis Sci. 1985 Jan;26(1):1-9
pubmed: 3967952
Br J Ophthalmol. 2004 Sep;88(9):1159-62
pubmed: 15317708
Int Ophthalmol. 1990 Oct;14(5-6):303-8
pubmed: 2249907
J Dent Res. 2018 Jul;97(8):946-953
pubmed: 29514008
Cell Metab. 2012 Nov 7;16(5):645-57
pubmed: 23102618
Ophthalmic Res. 2001 Sep-Oct;33(5):251-5
pubmed: 11586057
Mol Vis. 2012;18:1858-64
pubmed: 22815639
Drugs. 2005;65(4):497-519
pubmed: 15733012
J Immunol. 1996 Feb 15;156(4):1654-60
pubmed: 8568272
J Exp Med. 2008 Apr 14;205(4):799-810
pubmed: 18391061
J Immunol. 2015 Apr 1;194(7):3011-9
pubmed: 25716996
Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5439-49
pubmed: 26284549
J Immunol. 1988 Mar 1;140(5):1490-5
pubmed: 3346541
Parasite Immunol. 1994 Oct;16(10):521-7
pubmed: 7870462